Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...
Stockhead on MSN
ASX Quarterly Health Wrap: Strong early milestones set the pace
Rhythm Biosciences, Audeara and Island Pharmaceuticals among ASX health companies reporting milestones reached in quarterly ...
TORONTO, Jan. 20, 2026 /PRNewswire/ - i-80 GOLD CORP. (TSX:IAU) (NYSE American:IAUX) ("i-80 Gold", or the "Company") is ...
FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...
Q4 2025 Earnings Call January 20, 2026 10:00 AM ESTCompany ParticipantsMatt Curoe - Senior Director of Investor ...
Women neurologists of various subspecialties and career stages gathered for the 4th Annual Women in Neurology Conference, hosted by the Women Neurologists Group.
AINewsWire: Artificial intelligence and edge computing are increasingly recognized as foundational technologies for modern defense and autonomous systems. Experts note that defense operations must ...
ProMIS Neurosciences Inc. ("ProMIS" or the "Company"), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded ...
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the safety & security services industry, including MSA Safety (NYSE:MSA) and its peers. Rising concerns over ...
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...
On January 27, the University of Toronto, Mississauga (UTM) Academic Affairs Committee (AAC) met to review enrolment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results